Hassane M. Zarour

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

Medicine, Immunology, Oncology +17

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

Pharmacy, Oncology, Pharmacotherapy +17

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Diwakar Davar, Amiran Dzutsev, John A. McCulloch et al. · Science · 2021 · 1.6K citations · Full text

Life Sciences, Immunology, Oncology +17

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

Julien Fourcade, Zhaojun Sun, Mourad Benallaoua et al. · The Journal of Experimental Medicine · 2010 · 1.3K citations · Full text

Life Sciences, Immunology, Oncology +17

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas, Omid Hamid, Adil Daud et al. · JAMA · 2016 · 1.1K citations · Full text

Medicine, Immunology, Oncology +17